Scribd
Upload
38 views9 pages

Column4 Sun Pharma: Non Current Asset Tangible Assets

Uploaded by

Prateek Dadhich
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
38 views9 pages

Column4 Sun Pharma: Non Current Asset Tangible Assets

Uploaded by

Prateek Dadhich
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
You are on page 1/ 9

Column1 Column2 Column3 Column4

Sun
Pharma

ASSETS
NON CURRENT ASSET
Tangible Assets
Property, plant and Equipment 105,674.30
Capital work-in progress 6,589.10
Investment 52,457.50
Loans 7.9

Other Financial Assets 66644.2


other non-current assets 6,200.90
237,574

Intangible Assets

Goodwill 64,814.60
Other Intangible Asset 63594.5
128,409

365,983.0

CURRENT ASSET
Bank Balances other than Cash and Cash Equivalents 8109.4
Cash and Cash Equivalents 56766.1
Trade Receivables 94212.4
Inventories 78749.9
Investments 48973.6
Loans 1483.8
Other Financial Assets 9293.4
Other Current Assets 18953
316,541.6

TOTAL 682,524.6
Sl.No. Sl.No.
1 1
2
3
4
5
Column5 Column6

BALANCE SHEET AS ON 31ST March 2020

LIABILITIES
EQUITY
Equity Share Capital 2399.3
Other Equity 488,847.60

491,246.9
NON CURRENT LIABILITIES

Borrowings 20289.2
Other Financial Liabilities 424.1
Provisions 5110
Deferred Tax Liabilities (Net) 581.4
Other Non-Current Liabilities 7808.7

34,213.4

CURRENT LIABILITIES
Borrowings 55493.8
Trade Payables 40937.3
Other Financial Liabilities 12448.2
Provisions 39701.8
Current Tax Liabilities (Net) 2020.3
Other Current Liabilities 6462.9
157,064.3

191,277.7

682,524.6
Keyword Description Approach
Derivative it is a contr Internet
Deferred Tax Liabilities (Net) it is a tax wh Internet
Cash value Hedge Not able to Internet
FVTOCI Not able to Internet
Treasury shares acquired by ESOP Not able to Internet
Sun Pharma

Column1 Column2 Column3 Column4 Column5


PROFIT & LOSS ACCOUNT FOR THE PERIOD ENDED 31ST March 2020

EXPENSE INCOME
Cost of Materials Consumed 55152.3 Revenue from operation
Trade Purchases 34143.7 Other Income
Change in inventory 3008.5
Employee Benefits Expense 63623.5
Finance Cost 3027.3
Depreciation and Amortization 20527.8
Net Gain/Loss on foreign currency
transactions -156.1

Other Expenses 102705.5


282,032.5

Profit/ (Loss) before Exceptional Items and


Tax 52,702.3
Exceptional items 2606.4
Profit/ (Loss) before Tax 50,095.9
Column6 Column7

328375
6359.8

334,734.8
Sun Pharma

Cash Flow Statement for the year end March 2020


Cash Flow from Operating Activuities
Profit before tax 50,095.90
Adjustments for:
Depreciation and amortisation expense 20,527.80
Impairment of property, plant and
equipment, goodwill and other intangible 1.5
assets
Loss on sale / write off of property, plant
and equipment and other intangible assets, 52.20
net
Finance costs 3,027.30
Interest income -3,546.20
Dividend income on investments -561.8
Net gain arising on financial assets -571.9
measured at fair value through profit or loss
Net gain on sale of financial assets -246.7
measured at fair value through profit or loss
Net (gain)/ loss on sale of financial assets
measured at fair value through other -0.4
comprehensive income
Provision / write off /(reversal) for doubtful 1,068.10
trade receivables / advances
Sundry balances written back -52.2
Effect of exchange rate changes 227.7
Operating profit before working capital 70,021.30
changes
Movements in working capital:
(Increase) / Decrease in inventories 2,567.70
(Increase) / Decrease in trade receivables -3,740.50
((Increase) / Decrease in other assets -1,751.90
Increase / (Decrease) in trade payables -1,365.70
Increase / (Decrease) in other liabilities 2,363.30
Increase / (Decrease) in provisions 10,912.60
Cash generated from operations 79,006.80
Income tax paid (net of refund) -13,459.10
Net cash generated from operating 65,547.70
activities (A)
B. Cash flow from investing activities
Payments for purchase of property, plant
and equipment (including capital work-in- -15,420.00
progress, other intangible assets and
intangible assets under development)
Proceeds from disposal of property, plant 920.3
and equipment and other intangible assets
Loans / inter corporate deposits given / -191.30
placed
Loans / inter corporate deposits received 1,875.40
back / matured
Purchase of investments -334,453.90
Proceeds from sale of investments 318,936.30
Bank balances not considered as cash and
cash equivalents
Fixed deposits / margin money placed (9,694.5
Fixed deposits
Net cash / margin
outflow money matured
on acquisition of 8,192.90
subsidiary
Interest received 3,384.60
Dividend received 561.8
Net cash used in investing activities (B) -25,888.40
C. Cash flow from financing activities Column1
Proceeds from borrowings 105,515.70
Repayment of borrowings -138,934.60
Payment for buy-back of equity shares of
parent and buy-back of equity shares held -2,124.80
by noncontrolling interests of subsidiaries
Dividend payment to non-controlling interest -201.4
Net increase / (decrease) in working capital 2,189.00
demand loans
Proceeds from issue of equity shares on
exercise of stock options / share application
money received
Transfer to escrow account for buy-back -4,250.00
Finance costs -2,718.90
Dividend paid -13,791.90
Dividend distribution tax -2,834.50
Net cash used in financing activities (C) -57,151.40
Net (decrease) / increase in cash and cash -17,492.10
equivalents (A+B+C)
Cash and cash equivalents at the beginning 70,623.00
of the year
Cash and cash equivalents taken over on
acquisition of subsidiary
Effect of exchange differences on
restatement of foreign currency cash and 3,635.20
cash equivalents
Cash and cash equivalents at the end of the 56,766.10
year

Opening balance 105,143.60


Closing balance 79,708.50
Difference 25,435.10

You might also like